C - Chemistry – Metallurgy – 07 – K
Patent
C - Chemistry, Metallurgy
07
K
C07K 16/00 (2006.01) C07K 16/42 (2006.01)
Patent
CA 2694644
Pharmaceutical combinations comprising an .alpha.5.beta.1 antagonist in combination with a tyrosine kinase inhibitor. In some embodiments, the .alpha.5.beta.1 antagonist is volociximab. In some embodiments, the tyrosine kinase inhibitor is sunitinib or a pharmaceutically acceptable salt thereof. The invention also relates to methods for treating cancer by administering the pharmaceutical combinations to a subject.
L'invention concerne des combinaisons pharmaceutiques comprenant un antagoniste de a5b1 en combinaison avec un inhibiteur de tyrosine kinase. Dans certains modes de réalisation, l'antagoniste de a5b1 est du volociximab. Dans certains modes de réalisation, l'inhibiteur de tyrosine kinase est du sunitinib ou un sel pharmaceutiquement acceptable de celui-ci. L'invention concerne également des procédés pour traiter le cancer en administrant les combinaisons pharmaceutiques à un sujet.
Bhaskar Vinay
Ramakrishnan Vanitha
Facet Biotech Corporation
Smart & Biggar
LandOfFree
Pharmaceutical combinations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical combinations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical combinations will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1657071